Neumora Therapeutics expects cash to fund operations into 2026
PremiumThe FlyNeumora Therapeutics expects cash to fund operations into 2026
3M ago
Neumora Therapeutics reports Q2 EPS (37c), consensus (37c)
Premium
The Fly
Neumora Therapeutics reports Q2 EPS (37c), consensus (37c)
3M ago
3 Best Stocks to Buy Now, 7/23/2024, According to Top Analysts
Premium
Market News
3 Best Stocks to Buy Now, 7/23/2024, According to Top Analysts
4M ago
Neumora Therapeutics reports Q1 EPS (34c), consensus (34c)
PremiumThe FlyNeumora Therapeutics reports Q1 EPS (34c), consensus (34c)
6M ago
Neumora Therapeutics falls 23% after FDA clinical hold of Phase 1 NMRA-266 study
Premium
The Fly
Neumora Therapeutics falls 23% after FDA clinical hold of Phase 1 NMRA-266 study
7M ago
Neumora Therapeutics announces clinical hold of Phase 1 NMRA-266 study
Premium
The Fly
Neumora Therapeutics announces clinical hold of Phase 1 NMRA-266 study
7M ago
JPMorgan biotech analysts to hold an analyst/industry conference call
PremiumThe FlyJPMorgan biotech analysts to hold an analyst/industry conference call
9M ago
JPMorgan biotech analysts to hold an analyst/industry conference call
Premium
The Fly
JPMorgan biotech analysts to hold an analyst/industry conference call
9M ago
Neumora Therapeutics appoints Panandiker as Chief Commercial Officer
Premium
The Fly
Neumora Therapeutics appoints Panandiker as Chief Commercial Officer
10M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100